Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Elekta exercises share repurchase authorization

The Board of Directors of Elekta AB has decided to utilize the authorization received from the Annual General Meeting to repurchase shares in the company.

From Elekta 16 Jun 2010

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer. Results will provide researchers with a data needed to guide a phase 3 trial.

16 Jun 2010

Florida Advisory Council on Radiation Protection endorses ASTRO's Target Safely patient protection plan

Through a unanimous decision, the Florida Advisory Council on Radiation Protection has endorsed Target Safely, the American Society for Radiation Oncology's (ASTRO) patient protection plan.

16 Jun 2010

New cancer research centre launched in Edinburgh

Edinburgh today (Wednesday) becomes the next link in a unique chain of Cancer Research UK Centres that are being launched across the UK.

16 Jun 2010

ARBs may be linked with increased risk of developing cancer: US scientists

A common class of blood pressure drugs called angiotensin-receptor blockers may be linked with a slightly increased risk of developing cancer, US scientists have found.

16 Jun 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

Aeterna Zentaris announces $12.1 million registered direct offering

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has received commitments from institutional investors to purchase US$12.1 million of securities in a registered direct offering.

16 Jun 2010

Expected 97% accuracy in ovarian cancer detection: Study underway

Now scientists in Melbourne have found a more effective test to detect ovarian cancer and hope to commence trials soon. This new test will check for two additional biomarkers that may indicate ovarian cancer in addition to conventional tests.

15 Jun 2010

Diversity publication recognizes UH as a leader among health care institutions

DiversityInc, a leading publication on diversity and business, has recognized University Hospitals as a leader among health care institutions in its first ever Top Hospital Systems listing.

15 Jun 2010

Central Washington Hospital improves patient experience with Toshiba' Vantage Titan MR system

In today's demanding health care environment, many community hospitals require imaging equipment that provides a variety of advanced diagnostic exams with features that improve patient cooperation. To offer a variety of high-quality, comfortable MR exams to its patients, Central Washington Hospital in Wenatchee, Wash., selected Toshiba America Medical Systems' Vantage TitanTM MR system.

15 Jun 2010

CombiMatrix Diagnostics receives final licensure documentation and approvals to begin Medicare billing

CombiMatrix Corporation announced today that its laboratory services subsidiary, CombiMatrix Diagnostics, has received the final licensure documentation and approvals from Medicare in order to begin billing for its suite of array-based diagnostics tests.

15 Jun 2010

UBC announces launch of new office in Lörrach, Germany

United BioSource Corporation today announced the launch of a new office in Lörrach, Germany, further expanding the company's clinical research and medical affairs capabilities in Europe. The Lörrach office is located near Basel, Switzerland and is the 10th UBC office to open in Europe, adding to facilities in the United Kingdom, Switzerland, Ukraine, Spain, Sweden, Hungary and the Czech Republic.

15 Jun 2010

SQNM first-quarter 2010 total revenues up 22%: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Sequenom Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

15 Jun 2010

Pieris commences PRS-050 anti-VEGF Anticalin Phase I clinical trial for cancer

Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the compound's safety and tolerability in patients with solid tumors. Conducted at three sites in Germany, the trial is underway and patients from the first cohort have been dosed.

15 Jun 2010

EpiCept's common stock included on a list of preliminary additions to Russell Microcap Index

EpiCept Corporation announced today that the Company's common stock has been included on a list of preliminary additions to the Russell Microcap Index posted by Russell Investments on June 11, 2010 on www.russell.com. These changes are expected to go into effect after the close of trading on Friday, June 25, 2010.

15 Jun 2010

Aeterna Zentaris to present poster on AEZS-130 growth hormone secretagogue/ghrelin receptor agonist at 92nd ENDO

Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, will be presented at the upcoming 92nd Annual Endocrine Society (ENDO) Meeting and Expo, which will be held June 19 through 22, 2010 at the San Diego Convention Center in San Diego, California.

15 Jun 2010

Xoft reports clinical benefits of isotope-free electronic radiation therapy for treatment of cancer

The clinical benefits of isotope-free electronic radiation therapy delivered directly to cancer sites with minimal exposure to surrounding healthy tissue continues to be substantiated by multiple publications, according to Xoft, Inc., developer of the Axxent Electronic Brachytherapy, eBx System. The leading provider of FDA-cleared Electronic Brachytherapy Systems, Xoft provides systems for single-dose intraoperative radiation therapy and accelerated brachytherapy applications.

15 Jun 2010

Researchers discover microRNA biomarkers to treat patients with SCLC

Researchers at the Translational Genomics Research Institute, the Van Andel Research Institute and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have discovered a biomarker that could help in the treatment of patients with an aggressive type of lung cancer.

15 Jun 2010

Pediatric oncologist describes current state of science in combating neuroblastoma

Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge—much of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia.

15 Jun 2010

ExonHit Therapeutics, Genmab A/S sign agreement for selection of novel splice variants

ExonHit Therapeutics today announced the signing of an exclusive agreement with Genmab A/S for a selection of novel splice variants, identified as part of a successful pilot study, that have the potential to be therapeutic targets for breast cancer. Genmab retains exclusive development and commercialization rights on 10 events out of a breast cancer database developed using ExonHit's genome-wide SpliceArray technology (RNA splicing analysis platform covering the entire genome).

15 Jun 2010

Oncology News and Research

Further Reading

Elekta exercises share repurchase authorization

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

Florida Advisory Council on Radiation Protection endorses ASTRO's Target Safely patient protection plan

New cancer research centre launched in Edinburgh

ARBs may be linked with increased risk of developing cancer: US scientists

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Aeterna Zentaris announces $12.1 million registered direct offering

Expected 97% accuracy in ovarian cancer detection: Study underway

Diversity publication recognizes UH as a leader among health care institutions

Central Washington Hospital improves patient experience with Toshiba' Vantage Titan MR system

CombiMatrix Diagnostics receives final licensure documentation and approvals to begin Medicare billing

UBC announces launch of new office in Lörrach, Germany

SQNM first-quarter 2010 total revenues up 22%: MicroStockProfit.com

Pieris commences PRS-050 anti-VEGF Anticalin Phase I clinical trial for cancer

EpiCept's common stock included on a list of preliminary additions to Russell Microcap Index

Aeterna Zentaris to present poster on AEZS-130 growth hormone secretagogue/ghrelin receptor agonist at 92nd ENDO

Xoft reports clinical benefits of isotope-free electronic radiation therapy for treatment of cancer

Researchers discover microRNA biomarkers to treat patients with SCLC

Pediatric oncologist describes current state of science in combating neuroblastoma

ExonHit Therapeutics, Genmab A/S sign agreement for selection of novel splice variants

Event guide: The 9th DDR Inhibitors Summit 2026 eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News